Inspire Medical Systems Inc (INSP) Q1 2026 Earnings Call Transcript

Why It Matters

The revised outlook underscores heightened reimbursement risk and coding volatility, directly affecting profitability and investor confidence, while the new C code and strong clinical data aim to stabilize demand and support long‑term growth.

Key Takeaways

• Q1 revenue $204.6M, up 1.6% despite $20M hit
• Adjusted EBITDA margin rises to 17.5%, operating cash $12.8M
• Full-year revenue forecast cut to $825‑$875M, 9‑11% decline
• New CMS C code gives Medicare parity for Inspire V
• Clinical ADHERE trial shows cardiovascular benefits, supporting growth

Pulse Analysis

Inspire Medical Systems posted a solid yet cautious first‑quarter performance, delivering $204.6 million in revenue and an improved adjusted EBITDA margin of 17.5%. The modest top‑line growth masks a $20 million shortfall tied to coding ambiguities, reimbursement delays, and the government‑mandated WISER program. Despite these pressures, the company’s balance sheet remains robust, with $400 million in cash and no debt, giving it flexibility to navigate short‑term headwinds while investing in growth initiatives.

Reimbursement uncertainty has become a central theme for Inspire, as the transition to a new CMS C code for the Inspire V system seeks to resolve Medicare billing challenges. The C code aligns facility payments with the established Inspire IV CPT code, offering a temporary bridge until a permanent CPT code is expected in 2028. Meanwhile, the WISER program’s AI‑driven prior authorizations have slowed case volumes in six pilot states, prompting management to bolster field support and education. These operational adjustments aim to restore pipeline momentum and mitigate the projected $120‑$150 million revenue drag for the full year.

Beyond financial metrics, Inspire’s clinical pipeline strengthens its market position. The ADHERE real‑world trial, encompassing 5,000 patients, and a forthcoming cardiovascular outcomes study demonstrate significant health benefits over CPAP, including reduced stroke and heart failure incidents. Such data not only reinforce the therapeutic value of the Inspire system but also provide a compelling narrative for payers and providers. As the company prepares to showcase these results at the upcoming SLEEP conference, investors will be watching for evidence that can translate into sustained demand and improved profitability in a competitive sleep‑apnea market.